---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-359961"
form_type: "8-K"
ticker: "KLRS"
cik: "0001754068"
company_name: "Kalaris Therapeutics, Inc."
filed_at: "2021-12-17T23:59:59+00:00"
generated_at: "2026-06-28T00:10:40.146722+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# AlloVir CMO Agustin Melian to depart at year-end; Richard Riese to lead clinical programs

## Summary
- CMO Agustin Melian, MD, leaves AlloVir at end of 2021 after two and a half years.
- Melian will serve in an advisory role for transition; CEO thanked him for advancing posoleucel into Phase 3.
- Richard Riese, MD, PhD, SVP Clinical Research, will oversee clinical development including Phase 3 posoleucel studies.
- Company's pipeline of virus-specific T cells continues; no change to clinical strategy disclosed.

## SEC filing metadata
- accession: 0001193125-21-359961
- form_type: 8-K
- ticker: KLRS
- cik: 0001754068
- company_name: Kalaris Therapeutics, Inc.
- filed_at: 2021-12-17T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1754068/000119312521359961/0001193125-21-359961-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1754068/000119312521359961/d256659d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-359961
- JSON: https://secwatch.observer/filing/0001193125-21-359961.json
- Plain text: https://secwatch.observer/filing/0001193125-21-359961.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.